A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

High-risk acute promyelocytic leukemia (APL) remains a therapeutic challenge, with higher associated rates of early mortality and relapse than standard-risk APL. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) is a well-established treatment for patients with standard-risk APL, but it is...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Lancet, Jeffrey E., Moseley, Anna B., Coutre, Steven E., DeAngelo, Daniel J., Othus, Megan, Tallman, Martin S., Litzow, Mark R., Komrokji, Rami S., Erba, Harry P., Appelbaum, Frederick R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189292/
https://ncbi.nlm.nih.gov/pubmed/32330241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001278
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars